Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kourtis, Iraklis C ^a   Hirosue, Sachiko ^a   de Titta, Alexandre ^a   Kontos, Stephan ^a   Stegmann, Toon ^b   Hubbell, Jeffrey A ^a   Swartz, Melody A ^a  

^a EPFL   (Switzerland)

^b Mymetics BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; POLY(PROPYLENE SULFIDE); PROPYLENE; UNCLASSIFIED DRUG; FLUORESCENT DYE; LEUKOCYTE ANTIGEN; POLOXAMER; POLYMER; SULFIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BIOACCUMULATION; BIOAVAILABILITY; BIOTINYLATION; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL KINETICS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; LYMPHOID ORGAN; MACROPHAGE; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; T LYMPHOCYTE; ANIMAL; BLOOD; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPH NODE; LYMPHOMA; METABOLISM; MONOCYTE; PATHOLOGY; SPLEEN;

MUS;

ANIMALS; ANTIGENS, CD; BIOLOGICAL AVAILABILITY; DENDRITIC CELLS; FEMALE; FLUORESCENT DYES; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; LYMPH NODES; LYMPHOMA; MICE; MICE, INBRED C57BL; MONOCYTES; MYELOID CELLS; NANOPARTICLES; NEOPLASM TRANSPLANTATION; POLOXAMER; POLYMERS; SPLEEN; SULFIDES;

EID: 84876561994     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061646     Document Type: Article

References (57)

1. Davis ME, Chen ZG, Shin DM, (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
2. Taylor A, Wilson KM, Murray P, Fernig DG, Levy R, (2012) Long-term tracking of cells using inorganic nanoparticles as contrast agents: are we there yet? Chem Soc Rev 41: 2707-2717.
3. Bachmann MF, Jennings GT, (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787-796.
4. Petros RA, DeSimone JM, (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9: 615-627.
5. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, et al. (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520.
6. von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, et al. (2008) In vivo tumor cell targeting with "click" nanoparticles. Bioconjug Chem 19: 1570-1578.
7. Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M, (2011) Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta 1810: 317-329.
8. Hirosue S, Kourtis IC, van der Vlies AJ, Hubbell JA, Swartz MA, (2010) Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 28: 7897-7906.
9. Nembrini C, Stano A, Dane KY, Ballester M, van der Vlies AJ, et al. (2011) Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A 108: E989-997.
10. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, et al. (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 25: 1159-1164.
11. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ, (2010) Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 16: 1035-1041.
12. Schrand AM, Dai L, Schlager JJ, Hussain SM, (2012) Toxicity testing of nanomaterials. Adv Exp Med Biol 745: 58-75.
13. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, et al. (2008) Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38: 1404-1413.
14. Reddy ST, Swartz MA, Hubbell JA, (2006) Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 27: 573-579.
15. Jewell CM, Lopez SC, Irvine DJ, (2011) In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci U S A 108: 15745-15750.
16. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA, (2006) In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 112: 26-34.
17. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, et al. (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
18. Iannacone M, Moseman EA, Tonti E, Bosurgi L, Junt T, et al. (2010) Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature 465: 1079-1083.
19. Gonzalez SF, Lukacs-Kornek V, Kuligowski MP, Pitcher LA, Degn SE, et al. (2010) Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes. Nat Immunol 11: 427-434.
20. Roozendaal R, Mempel TR, Pitcher LA, Gonzalez SF, Verschoor A, et al. (2009) Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 30: 264-276.
21. Ballester M, Nembrini C, Dhar N, de Titta A, de Piano C, et al. (2011) Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 29: 6959-6966.
22. Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, et al. (2001) Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7: 199-205.
23. van der Vlies AJ, O'Neil CP, Hasegawa U, Hammond N, Hubbell JA, (2010) Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins. Bioconjug Chem 21: 653-662.
24. Cribari-Neto F, Zeileis A, (2010) Beta Regression in R. Journal of Statistical Software 34: 1-24.
25. Maldiney T, Richard C, Seguin J, Wattier N, Bessodes M, et al. (2011) Effect of core diameter, surface coating, and PEG chain length on the biodistribution of persistent luminescence nanoparticles in mice. ACS Nano 5: 854-862.
26. Phan TG, Grigorova I, Okada T, Cyster JG, (2007) Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 8: 992-1000.
27. Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, et al. (2007) Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450: 110-114.
28. Kang YS, Kim JY, Bruening SA, Pack M, Charalambous A, et al. (2004) The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen. Proc Natl Acad Sci U S A 101: 215-220.
29. Hickman HD, Li L, Reynoso GV, Rubin EJ, Skon CN, et al. (2011) Chemokines control naive CD8+ T cell selection of optimal lymph node antigen presenting cells. J Exp Med 208: 2511-2524.
30. de Jong EC, Smits HH, Kapsenberg ML, (2005) Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol 26: 289-307.
31. Steinman RM, (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30: 1-22.
32. Steinman RM, (2007) Dendritic cells: understanding immunogenicity. Eur J Immunol 37 Suppl 1: S53-60.
33. McLellan AD, Kampgen E, (2000) Functions of myeloid and lymphoid dendritic cells. Immunol Lett 72: 101-105.
34. Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z, et al. (2004) CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21: 279-288.
35. Tal O, Lim HY, Gurevich I, Milo I, Shipony Z, et al. (2011) DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J Exp Med 208: 2141-2153.
36. den Haan JM, Lehar SM, Bevan MJ, (2000) CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192: 1685-1696.
37. Gasparini R, Lai P, (2010) Utility of virosomal adjuvated influenza vaccines: a review of the literature. J Prev Med Hyg 51: 1-6.
38. Kaneda Y, (2012) Virosome: a novel vector to enable multi-modal strategies for cancer therapy. Adv Drug Deliv Rev 64: 730-738.
39. Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, et al. (2010) Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 4: 6629-6638.
40. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, et al. (2009) Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 32: 118-128.
41. Kang SM, Song JM, Kim YC, (2012) Microneedle and mucosal delivery of influenza vaccines. Expert Rev Vaccines 11: 547-560.
42. Nicolas JF, Guy B, (2008) Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 7: 1201-1214.
43. Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, et al. (2003) Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 301: 1925-1928.
44. Reis e Sousa C, (2006) Dendritic cells in a mature age. Nat Rev Immunol 6: 476-483.
45. Thomas SN, Rutkowski JM, Pasquier M, Kuan EL, Alitalo K, et al. (2012) Impaired Humoral Immunity and Tolerance in K14-VEGFR-3-Ig Mice That Lack Dermal Lymphatic Drainage. J Immunol 189: 2181-2190.
46. Katakai T, Hara T, Sugai M, Gonda H, Shimizu A, (2004) Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J Exp Med 200: 783-795.
47. Mebius RE, Kraal G, (2005) Structure and function of the spleen. Nat Rev Immunol 5: 606-616.
48. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, et al. (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325: 612-616.
49. Stephan MT, Stephan S, Bak SP, Chen J, Irvine DJ, (2012) Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials in press.
50. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
51. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
52. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA, (2010) Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328: 749-752.
53. Nagaraj S, Gabrilovich DI, (2010) Myeloid-derived suppressor cells in human cancer. Cancer J 16: 348-353.
54. Ostrand-Rosenberg S, Sinha P, (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506.
55. Buono C, Anzinger JJ, Amar M, Kruth HS, (2009) Fluorescent pegylated nanoparticles demonstrate fluid-phase pinocytosis by macrophages in mouse atherosclerotic lesions. J Clin Invest 119: 1373-1381.
56. Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, et al. (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29: 1005-1010.
57. Shi C, Pamer EG, (2011) Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11: 762-774.